Phenobarbital Sodium 130 mg/mL
Phenobarbital Sodium · INJECTION · Cameron Pharmaceuticals
Phenobarbital Sodium is a injection containing phenobarbital sodium at 130 mg/mL, taken intramuscular. Manufactured by Cameron Pharmaceuticals.
Key Facts
- Brand Name
- Phenobarbital Sodium
- Generic Name
- Phenobarbital Sodium
- NDC Code (Product)
42494-416- Manufacturer
- Cameron Pharmaceuticals
- Strength
- 130 mg/mL
- Dosage Form
- INJECTION
- Route
- INTRAMUSCULAR
- Marketing Status
- DEA Schedule
- Schedule IV (Controlled)
- Marketing Start
- 02/05/2020
Recall History
Vitae Enim Vitae Scientific, Inc.
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Vitae Enim Vitae Scientific, Inc.
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Side Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE Parenteral Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated w…
Dosage & Administration
DOSAGE AND ADMINISTRATION Dosages of barbiturates must be individualized with full knowledge of their particular characteristics and recommended rates of administration. Factors to consider are the patient's age, weight and condition. Suggested doses of phenobarbital sodium for specific indications follow: Pediatric Dosage Recommended by the American Academy of Pediatrics (intended as a guide) Preoperative Sedation: 1 to 3 mg/kg IM or IV Anticonvulsant: 4 to 6 mg/kg/day for 7 to 10 days to blood level of 10 to 15 mcg/mL or 10 to 15 mg/kg/day IM or IV Status Epilepticus: 15 to 20 mg/kg over 10 to 15 minutes IV Adult Dosage (intended as a guide) Daytime Sedation: 30 to 120 mg daily in 2 to 3 divided doses IM or IV Bedtime Hypnosis: 100 to 320 mg IM or IV Preoperative Sedation: IM only — 100 to 200 mg 60 to 90 minutes before surgery Acute Convulsions: 20 to 320 mg IM or IV, repeated in 6 hours as necessary Parenteral routes should be used only when oral administration is impossible or impractical. Intramuscular injection of the sodium salts of barbiturates should be made deeply into a large muscle and a volume of 5 mL should not be exceeded at any one site because of possible tissue i…
Warnings
WARNINGS Phenobarbital Sodium Injection contains the preservative benzyl alcohol and is not recommended for use in neonates. There have been reports of fatal 'gasping syndrome' in neonates (children less than one month of age) following the administration of intravenous solutions containing the preservative benzyl alcohol. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse. Habit Forming Barbiturates may be habit forming. Tolerance and psychological and physical dependence may occur with continued use (see DRUG ABUSE AND DEPENDENCE and CLINICAL PHARMACOLOGY ). Patients who are psychologically dependent on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates. To minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions and…
Contraindications
CONTRAINDICATIONS Barbiturates are contraindicated in patients with known barbiturate sensitivity. Barbiturates are also contraindicated in patients with a history of manifest or latent porphyria, marked impairment of liver functions or with severe respiratory distress where dyspnea or obstruction is evident. Large doses are contraindicated in nephritic subjects. Barbiturates should not be administered to persons with known previous addiction to the sedative-hypnotic group since ordinary doses may be ineffectual and may contribute to further addiction. Intraarterial administration is contraindicated. Its consequences vary from transient pain to gangrene. Subcutaneous administration produces tissue irritation, ranging from tenderness and redness to necrosis and is not recommended. (See DOSAGE AND ADMINISTRATION, Treatment of Adverse Effects Due to Inadvertent Error in Administration .)
Drug Interactions
Drug Interactions Most reports of clinically significant drug interactions occuring with the barbiturates have involved phenobarbital. However, the application of these data to other barbiturates appears valid and warrants serial blood level determinations of the relevant drugs when there are multiple therapies. Anticoagulants Phenobarbital lowers the plasma levels of dicumarol (bishydroxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time. Barbiturates can induce hepatic microsomal enzymes resulting in increased metabolism and decreased anticoagulant response of oral anticoagulants (e.g., warfarin, acenocoumarol, dicumarol and phenprocoumon). Patients stabilized on anticoagulant therapy may require dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen. Corticosteroids Barbiturates appear to enhance the metabolism of exogenous corticosteroids probably through the induction of hepatic microsomal enzymes. Patients stabilized on corticosteroid therapy may require dosage adjustments if barbiturates are added to or withdrawn from thier dosage regimen. Griseofulvin Phenobarbital appears to interfere with the absor…
Adverse Reactions
ADVERSE REACTIONS The following adverse reactions and their incidence were compiled from surveillance of thousands of hospitalized patients. Because such patients may be less aware of certain of the milder adverse effects of barbiturates, the incidence of these reactions may be somewhat higher in fully ambulatory patients. Nervous System Somnolence, agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality Respiratory System Hypoventilation, apnea Cardiovascular System Bradycardia, hypotension, syncope Digestive System Nausea, vomiting, constipation Dermatologic Reactions Exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermic necrolysis. Other Reported Reactions Headache; injection site reactions; hypersensitivity reactions, including but not limited to angioedema and skin rashes; fever; liver damage and megaloblastic anemia following chronic phenobarbital use.
Frequently Asked Questions
What is Phenobarbital Sodium used for?
Phenobarbital Sodium contains Phenobarbital Sodium. It is a injection taken intramuscular. Consult your doctor for specific uses.
Is Phenobarbital Sodium a controlled substance?
Yes, Phenobarbital Sodium is classified as CIV under the DEA Controlled Substances Act.
What is the generic name for Phenobarbital Sodium?
The generic name for Phenobarbital Sodium is Phenobarbital Sodium. There are 1 other brand versions of Phenobarbital Sodium.
What is the NDC code for Phenobarbital Sodium 130 mg/mL?
The NDC (National Drug Code) for Phenobarbital Sodium 130 mg/mL is 42494-416, listed by Cameron Pharmaceuticals.
Other Phenobarbital Sodium Dosages
- Phenobarbital Sodium130 mg/mL0641-0477
- Phenobarbital Sodium65 mg/mL54288-136
- Phenobarbital Sodium65 mg/mL71335-3004
- Phenobarbital Sodium130 mg/mL54288-137
- Phenobarbital Sodium130 mg/mL63629-1997
- Phenobarbital Sodium130 mg/mL72162-1330
- Phenobarbital Sodium130 mg/mL14789-128
- Phenobarbital Sodium65 mg/mL42494-415
- Phenobarbital Sodium130 mg/mL42494-442
- Phenobarbital Sodium65 mg/mL63629-1998
Other Phenobarbital Brands
See all →Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)